Skip to content

Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00558532
Enrollment
0
Registered
2007-11-15
Start date
2007-10-31
Completion date
2008-11-30
Last updated
2016-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Fatty Acid Levels, Morbid Obesity

Keywords

Morbid obesity, Omega-3 fatty acid levels

Brief summary

The purpose of this study is to determine the concentration of omega-3 fatty acids in plasma, blood and abdominal fat before and after bariatric surgery to provide guidance for future studies.

Detailed description

The omega-3 fatty acids are essential for human growth, development and well-being. Numerous studies have shown that a relatively high intake of the omega-3 fatty acids are beneficial in brain and visual development, psychiatric disorders, rheumatic disorders, inflammatory responses and cardiovascular disease. As an example, low levels of tissue omega-3 fatty acids are associated with a markedly higher rate of death from cardiac causes compared to patients with relatively high concentrations of the omega-3 fatty acids. Obese patients often have an unhealthy dietary intake and evidence of increased inflammatory processes. After a gastric bypass patients will have decreased absorption of fats from the gastrointestinal tract and may become fatty acid deficient. While gastric bypass may decrease death from cardiovascular disease in morbidly obese patients, cardiovascular disease is still the most common cause of death after a gastric bypass. There are numerous nutritional deficiencies which occur after gastric bypass and many of these are well documented. However, there are no data concerning the plasma and tissue levels of omega-3 fatty acids in morbidly obese patients either before or after operation.

Interventions

PROCEDUREBariatric Surgery

Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery

Sponsors

University of Cincinnati
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Surgical group candidates must be undergoing surgery for morbid obesity, abdominoplasty or other abdominal operation. * Must have adequate venous access.

Exclusion criteria

* Insufficient venous access

Design outcomes

Primary

MeasureTime frame
Omega-3 Fatty acid levels in whole blood, plasma and abdominal fat sampleWithin 3 months of surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026